title: Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
authors.forename: B
authors.initials: B
authors.lastname: Martin-Castillo
authors.forename: J
authors.initials: J
authors.lastname: Dorca
authors.forename: A
authors.initials: A
authors.lastname: Vazquez-Martin
authors.forename: C
authors.initials: C
authors.lastname: Oliveras-Ferraros
authors.forename: E
authors.initials: E
authors.lastname: Lopez-Bonet
authors.forename: M
authors.initials: M
authors.lastname: Garcia
authors.forename: S
authors.initials: S
authors.lastname: Del Barco
authors.forename: J A
authors.initials: JA
authors.lastname: Menendez
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D007558:Italy; D008687:Metformin / Q000627:therapeutic use*; D020360:Neoadjuvant Therapy; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics; D057170:Translational Research, Biomedical; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008687:Metformin; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab